Sacituzumab govitecan in Japanese participants with HR+/HER2- metastatic breast cancer: primary results from the phase II ASCENT-J02 study.

Shimomura A, Kogawa T, Matsumoto K, Watanabe J, Watanabe K, Nakayama T, Shien T, Iwasa T, Padman S, Huynh D, Shao J, Kwan J, Iwahori Y, Naito Y, Iwata H

Open source

DOI: 10.1093/jjco/hyag043
Published: 2026 Jul 6
Container: Japanese journal of clinical oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/jjco/hyag043,
  title = {Sacituzumab govitecan in Japanese participants with HR+/HER2- metastatic breast cancer: primary results from the phase II ASCENT-J02 study.},
  author = {Shimomura A and Kogawa T and Matsumoto K and Watanabe J and Watanabe K and Nakayama T and Shien T and Iwasa T and Padman S and Huynh D and Shao J and Kwan J and Iwahori Y and Naito Y and Iwata H},
  year = {2026},
  journal = {Japanese journal of clinical oncology},
  doi = {10.1093/jjco/hyag043},
  url = {https://doi.org/10.1093/jjco/hyag043}
}

RIS

TY  - JOUR
TI  - Sacituzumab govitecan in Japanese participants with HR+/HER2- metastatic breast cancer: primary results from the phase II ASCENT-J02 study.
AU  - Shimomura A
AU  - Kogawa T
AU  - Matsumoto K
AU  - Watanabe J
AU  - Watanabe K
AU  - Nakayama T
AU  - Shien T
AU  - Iwasa T
AU  - Padman S
AU  - Huynh D
AU  - Shao J
AU  - Kwan J
AU  - Iwahori Y
AU  - Naito Y
AU  - Iwata H
PY  - 2026
JO  - Japanese journal of clinical oncology
DO  - 10.1093/jjco/hyag043
UR  - https://doi.org/10.1093/jjco/hyag043
ER  -

APA

A, S., T, K., K, M., J, W., K, W., T, N., T, S., T, I., S, P., D, H., J, S., J, K., Y, I., Y, N., & H, I. (2026). Sacituzumab govitecan in Japanese participants with HR+/HER2- metastatic breast cancer: primary results from the phase II ASCENT-J02 study.. Japanese journal of clinical oncology. https://doi.org/10.1093/jjco/hyag043

Source records

pubmed · retrieved 2026-09-27T09:56:51.931Z
europe-pmc · retrieved 2026-09-27T09:56:51.942Z